Howland Capital Management 13F: Cuts PSNL Stake by $3.7M

Howland Capital Management reduced its stake in Personalis, Inc. PSNL by 41.1%, selling 228,253 shares during the quarter according to a Form 13F filed with the SEC on October 22, 2026.

PSNL Personalis, Inc.

$15.82 ▲ +101.53% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in Howland Capital Management's Personalis Position

The firm trimmed its holdings to 327,388 shares, down from 555,641 shares in the previous period. The remaining stake carried a reported value of $5,329,877 as of the filing date.

Other Institutional Activity in Personalis

Other large funds made notable adjustments to their Personalis positions during the quarter. Merck & Co., Inc. kept its holdings steady with 14,044,943 shares valued at $222,190,993. ARK Investment Management, LLC grew its holdings by 327,295 shares, ending with 8,271,339 shares worth about $130,852,580. Lightspeed Management Company, L.L.C. reduced its position by 2,058,977 shares, finishing with 6,101,850 shares valued at $96,531,265. Ameriprise Financial, Inc. cut its stake by 1,506,393 shares, leaving it with 6,086,315 shares worth about $96,285,501. Deep Track Capital, Lp increased its holdings by 999,925 shares for a 33.3% gain, ending with 4,000,000 shares valued at $63,279,998.

Personalis, Inc. Stock Down 0.5%

Personalis shares closed at $15.82 on October 22, 2026, and recently traded around $15.82 on October 23, 2026. The stock has traded between a 52-week low of $4.96 and a 52-week high of $18.89.

Recent Earnings

Personalis reported $69.67 million in trailing twelve-month revenue alongside a basic EPS of -$1.09. The company's next financial update is scheduled for November 3, 2026.

Insider Buying and Selling at Personalis, Inc.

Company insiders sold shares ahead of the filing period. On September 18, 2026, President Richard Chen sold 3,998 shares at an average price of $16.22 for a total value of $64,848. Officer Stephen Michael Moore sold 2,068 shares at $16.22 for $33,543. Chief Operating Officer Aaron Tachibana sold 2,931 shares at $16.22 for $47,541. Chief Executive Officer Christopher M. Hall sold 7,459 shares at $16.22 for $120,985. None of these transactions were made under a pre-arranged Rule 10b5-1 plan.

Analysts Set New Price Targets

Wall Street firms updated their views on the diagnostics company over the summer and fall. On July 17, 2026, Needham maintained a Buy rating and raised its price target from $12.00 to $17.00. Lake Street downgraded the stock to a Hold rating with a $16.25 price target on July 20, 2026. BTIG maintained a Buy rating on July 20, 2026, lifting its target from $11.00 to $16.25. Needham also downgraded the stock to a Hold rating on July 20, 2026. Later, on October 6, 2026, BTIG downgraded the stock to a Neutral rating.

About Personalis

Personalis, Inc. develops and markets advanced cancer genomic tests and diagnostic services. Headquartered in Fremont, California, the company focuses on precision oncology tools designed to help clinicians analyze tumors and monitor patient treatment responses.

Bottom Line

Investors will look to the upcoming earnings release on November 3, 2026, for further updates on Personalis's financial health and test adoption rates. Institutional ownership shifts will become clearer in subsequent quarterly filings.